Clinical causes and treatment of the thrombotic storm

Expert Review of Hematology

Volumn 5, Issue 6, 2012, Pages 653-659

  Ortel, Thomas L ^a   Kitchens, Craig S ^b   Erkan, Doruk ^c   Brandão, Leonardo R ^d   Hahn, Susan ^e   James, Andra H ^f   Kulkarni, Roshni ^g   Manco Johnson, Marilyn J ^h   Pericak Vance, Margaret ^e   Vance, Jeffery ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Catastrophic antiphospholipid syndrome; Genetics; Inherited thrombophilia; Thromboembolism; Thrombotic storm

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 5 LEIDEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RITUXIMAB; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL CIRCULATION; BLOOD CLOTTING DISORDER; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FIBRINOLYTIC THERAPY; HEREDITY; HUMAN; IMMUNOMODULATION; LABORATORY DIAGNOSIS; LONG TERM CARE; LUNG EMBOLISM; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC EVENT; TREATMENT OUTCOME; VENOUS CIRCULATION; PATHOLOGY; THROMBOPHILIA; THROMBOSIS;

ANTICOAGULANTS; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 84870929716     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.56     Document Type: Review

References (59)

1. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), 419S-494S (2012).
2. Vandvik PO, Lincoff AM, Gore JM et al.; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), 637S-668S (2012).
3. Alonso-Coello P, Bellmunt S, McGorrian C et al.; American College of Chest Physicians. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), 669S-690S (2012).
4. Kwaan HC. Microvascular thrombosis: a serious and deadly pathologic process in multiple diseases. Semin. Thromb. Hemost. 37(8), 961-978 (2011).
5. Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83(5), 1251-1257 (1994).
6. Monagle P, Newall F, Barnes C et al. Arterial thromboembolic disease: a single-centre case series study. J. Paediatr. Child Health 44(1-2), 28-32 (2008).
7. deVeber G, Andrew M, Adams C et al.; Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N. Engl. J. Med. 345(6), 417-423 (2001).
8. Kirkham F, Sébire G, Steinlin M, Sträter R. Arterial ischaemic stroke in children. Review of the literature and strategies for future stroke studies. Thromb. Haemost. 92(4), 697-706 (2004).
9. Raffini L, Raybagkar D, Cahill AM, Kaye R, Blumenstein M, Manno C. May-Thurner syndrome (iliac vein compression) and thrombosis in adolescents. Pediatr. Blood Cancer 47(6), 834-838 (2006).
10. Brandão LR, Williams S, Kahr WH, Ryan C, Temple M, Chan AK. Exerciseinduced deep vein thrombosis of the upper extremity. 2. A case series in children. Acta Haematol. 115(3-4), 221-229 (2006).
11. Nowak-Göttl U, Junker R, Kreuz W et al.; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 97(4), 858-862 (2001).
12. Young G, Albisetti M, Bonduel M et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 118(13), 1373-1382 (2008).
13. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int. Suppl. 112, 8-10 (2009).
14. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu. Rev. Pathol. 3, 249-277 (2008).
15. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 80(6), 355-377 (2001).
16. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am. J. Med. 104(4), 381-385 (1998).
17. Kitchens CS, Erkan D, Brandão LR et al. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am. J. Med. 124(4), 290-296 (2011).
18. Hayashi T, Lee S, Ogasawara H et al. Exacerbation of systemic lupus erythematosus related to cytomegalovirus infection. Lupus 7(8), 561-564 (1998).
19. Douglas KW, Pollock KG, Young D, Catlow J, Green R. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J. Clin. Apher. 25(2), 47-53 (2010).
20. Cervera R, Bucciarelli S, Plasín MA et al.; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the 'CAPS Registry'. J. Autoimmun. 32(3-4), 240-245 (2009).
21. Male C, Foulon D, Hoogendoorn H et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 106(13), 4152-4158 (2005).
22. Manco-Johnson MJ, Wang M, Goldenberg NA et al. Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. J. Pediatr. 161(4), 682.e1-688.e1 (2012).
23. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295-306 (2006).
24. Pengo V, Ruffatti A, Legnani C et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118(17), 4714-4718 (2011).
25. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann. Intern. Med. 135(8 Pt 1), 589-593 (2001).
26. Moreb J, Kitchens CS. Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases. Am. J. Med. 87(2), 207-210 (1989).
27. Ingram SB, Goodnight SH Jr, Bennett RM. An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies: report of two cases. Arthritis Rheum. 30(10), 1167-1172 (1987).
28. Bird AG, Lendrum R, Asherson RA, Hughes GR. Disseminated intravascular coagulation, antiphospholipid antibodies, and ischaemic necrosis of extremities. Ann. Rheum. Dis. 46(3), 251-255 (1987).
29. Asherson RA. The catastrophic antiphospholipid syndrome. J. Rheumatol. 19(4), 508-512 (1992).
30. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun. Rev. 10(2), 74-79 (2010).
31. Cervera R, Khamashta MA, Shoenfeld Y et al.; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 68(9), 1428-1432 (2009).
32. Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 18(10), 905-912 (2009).
33. Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J. Rheumatol. 34(2), 346-352 (2007).
34. Erkan D, Asherson RA, Espinosa G et al.; Catastrophic Antiphospholipid Syndrome Registry Project Group. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann. Rheum. Dis. 62(6), 530-533 (2003).
35. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am. J. Med. 121(7), 632-636 (2008).
36. Jay RM, Warkentin TE. Fatal heparininduced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? J. Thromb. Haemost. 6(9), 1598-1600 (2008).
37. Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. J. Thromb. Haemost. 7(3), 499-501 (2009).
38. Khorana AA. Cancer and coagulation. Am. J. Hematol. 87(Suppl. 1), 82-87 (2012).
39. Majumder S, Thom T, Dasanu CA. Catastrophic arteriovenous thromboembolism as initial manifestation of pancreatic cancer. JOP 13(2), 231-234 (2012).
40. Williams E, Smart SC, Go RS. Catastrophic thromboembolism in a patient with acute lymphoblastic leukemia and hypereosinophilia. Haematologica 89(4), EIM01 (2004).
41. van Gestel JP, Merks JH, Lo RT, Kappelle JL, Braun KP. A child with multifocal arterial thrombosis. Thromb. Haemost. 93(5), 995-996 (2005).
42. Zöller B, Li X, Sundquist J, Sundquist K. Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden. J. Intern. Med. 270(2), 158-165 (2011).
43. Sharma A, Itha S, Baijal SS, Gupta R, Sonkar A, Aggarwal R. Superior sagittal sinus thrombosis and Budd-Chiari syndrome due to paroxysmal nocturnal hemoglobinuria managed with transjugular intrahepatic portosystemic shunt: a case report. Trop. Gastroenterol. 26(3), 146-148 (2005).
44. Kwon CM, Lee SH, Kim JH et al. A case of Behçet's disease with pericarditis, thrombotic thrombocytopenic purpura, deep vein thrombosis and coronary artery pseudo aneurysm. Korean J. Intern. Med. 21(1), 50-56 (2006).
45. Liu H, Al-Quran SZ, Lottenberg R. Thrombotic storm in Kimura disease. J. Thromb. Thrombolysis 29(3), 354-357 (2010).
46. Jeanneret C, Reutlinger C, Hirsch HH et al. Multifocal thrombophlebitis and deep vein thrombosis in primary cytomegalovirus infection-a histopathological analysis. Thromb. Haemost. 99(2), 445-447 (2008).
47. Ferri M, Faggioli G, Fratesi F, Stella A. Multifocal arterial thrombosis during thalidomide therapy: case report and review of the literature. Case Report. Med. 2009, 372073 (2009).
48. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb. Haemost. 94(1), 132-135 (2005).
49. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu. Rev. Med. 61, 77-90 (2010).
50. Omran AS, Karimi A, Ahmadi H, Yazdanifard P. Delayed-onset heparininduced thrombocytopenia presenting with multiple arteriovenous thromboses: case report. J. Med. Case Rep. 1, 131 (2007).
51. Refaai MA, Warkentin TE, Axelson M, Matevosyan K, Sarode R. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: a consequence of heparin 'flushes'. Thromb. Haemost. 98(5), 1139-1140 (2007).
52. Zivelin A, Gitel S, Griffin JH et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 94(3), 895-901 (1999).
53. Hoylaerts MF, Thys C, Arnout J, Vermylen J. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc γ RII receptor-mediated platelet activation. Blood 91(8), 2810-2817 (1998).
54. Sarode R. Atypical presentations of thrombotic thrombocytopenic purpura: a review. J. Clin. Apher. 24(1), 47-52 (2009).
55. Imanirad I, Rajasekhar A, Zumberg M. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J. Clin. Apher. 27(4), 221-226 (2012).
56. Josephson C, Nuss R, Jacobson L et al. The varicella-autoantibody syndrome. Pediatr. Res. 50(3), 345-352 (2001).
57. Manco-Johnson MJ, Nuss R, Key N et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J. Pediatr. 128(3), 319-323 (1996).
58. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43(8), 1467-1472 (1993).
59. O'Roak BJ, Vives L, Girirajan S et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485(7397), 246-250 (2012).